Back to Archived Journals » Antibody Technology Journal » Volume 2
Human hybridoma technology
Authors Gorny M
Received 23 June 2012
Accepted for publication 17 July 2012
Published 31 August 2012 Volume 2012:2 Pages 1—5
DOI https://doi.org/10.2147/ANTI.S30489
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Miroslaw K Gorny
Department of Pathology, New York University Langone School of Medicine, New York, NY, USA
Abstract: In light of recent developments in the production of human monoclonal antibodies, particularly the method based on isolation of immunoglobulin genes from antigen-specific B cells, the hybridoma technology has become obsolete to some extent. However, the method requires a relatively simple procedure at a low cost and has inherently valuable features, including continuous production of the whole molecule of specific antibodies that retain their native structure. Furthermore, several technical improvements, including accessibility to a panel of various partner cells, enhanced Epstein–Barr virus transformation and optimized electroporation, have increased the fusion efficiency for production of hybrids. Finally, a hybridoma-produced monoclonal antibody (mAb) can be used to test whether certain functions of a recombinant mAb, produced by molecular techniques from the same clone of B cells, correspond to the native antibodies. Access to several different methods of mAb production, including hybridoma technology, potentiates our capability to understand the human immune response to various invading pathogens and tumors with the perspective of using the antibodies for diagnosis and therapy.
Keywords: hybridoma, human monoclonal antibody, B cells
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.